IMWG consensus on risk stratification in multiple myeloma

W.J. Chng, A. Dispenzieri, C.-S. Chim, R. Fonseca, H. Goldschmidt, S. Lentzsch, N. Munshi, A. Palumbo, J.S. Miguel, P. Sonneveld, M. Cavo, S. Usmani, B.G. Durie, H. Avet-Loiseau, Dina Ben-Yehuda-Salz

Research output: Contribution to journalArticlepeer-review

450 Scopus citations


Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies. © 2014 Macmillan Publishers Limited.
Original languageEnglish
Pages (from-to)269-277
Number of pages9
Issue number2
StatePublished - 2014

Bibliographical note

Cited By :408

Export Date: 3 October 2022


Correspondence Address: Chng, W.J.; Department of Haematology-Oncology, 1E Lower Kent Ridge Road, Singapore 119228, Singapore; email:

References: Rajkumar, S.V., Treatment of multiple myeloma (2011) Nat Rev Clin Oncol, 8, pp. 479-491; Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Improved survival in multiple myeloma and the impact of novel therapies (2008) Blood, 111, pp. 2516-2520; Stewart, A.K., Richardson, P.G., San-Miguel, J.F., How i treat multiple myeloma in younger patients (2009) Blood, 114, pp. 5436-5443; Keats, J.J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.J., Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma (2007) Cancer Cell, 12, pp. 131-144; Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide (2011) Blood, 118, pp. 4771-4779; Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M.A., Blade, J., Mateos, M.V., Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN) (2011) Blood, 118, pp. 4519-4529; Ludwig, H., Bolejack, V., Crowley, J., Blade, J., Miguel, J.S., Kyle, R.A., Survival and years of life lost in different age cohorts of patients with multiple myeloma (2010) J Clin Oncol, 28, pp. 1599-1605; Avet-Loiseau, H., Attal, M., Campion, L., Caillot, D., Hulin, C., Marit, G., Long-term analysis of the IFM 99 trials for myeloma: Cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival (2012) J Clin Oncol, 30, pp. 1949-1952; Greipp, P.R., Lust, J.A., O'Fallon, W.M., Katzmann, J.A., Witzig, T.E., Kyle, R.A., Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma (1993) Blood, 81, pp. 3382-3387; Nowakowski, G.S., Witzig, T.E., Dingli, D., Tracz, M.J., Gertz, M.A., Lacy, M.Q., Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma (2005) Blood, 106, pp. 2276-2279; Greipp, P.R., Leong, T., Bennett, J.M., Gaillard, J.P., Klein, B., Stewart, J.A., Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group (1998) Blood, 91, pp. 2501-2507; Munshi, N.C., Anderson, K.C., Bergsagel, P.L., Shaughnessy, J., Palumbo, A., Durie, B., Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2 (2011) Blood, 117, pp. 4696-4700; Fonseca, R., Bergsagel, P.L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A.K., International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review (2009) Leukemia, 23, pp. 2210-2221; Avet-Loiseau, H., Role of genetics in prognostication in myeloma (2007) Best Pract Res Clin Haematol, 20, pp. 625-635; Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, R.A., Clinical and biologic implications of recurrent genomic aberrations in myeloma (2003) Blood, 101, pp. 4569-4575; Avet-Loiseau, H., Malard, F., Campion, L., Magrangeas, F., Sebban, C., Lioure, B., Translocation t(14;16) and multiple myeloma: Is it really an independent prognostic factor? (2011) Blood, 117, pp. 2009-2011; Boyd, K.D., Ross, F.M., Chiecchio, L., Dagrada, G.P., Konn, Z.J., Tapper, W.J., A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial (2012) Leukemia, 26, pp. 349-355; Hanamura, I., Stewart, J.P., Huang, Y., Zhan, F., Santra, M., Sawyer, J.R., Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation (2006) Blood, 108, pp. 1724-1732; Fonseca, R., Van Wier, S.A., Chng, W.J., Ketterling, R., Lacy, M.Q., Dispenzieri, A., Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma (2006) Leukemia, 20, pp. 2034-2040; Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome (2007) Blood, 109, pp. 3489-3495; Hebraud, B., Leleu, X., Lauwers-Cances, V., Roussel, M., Caillot, D., Marit, G., Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: The IFM experience on 1195 patients (2013) Leukemia, , e-pub ahead of print 29 July 2013; doi: 10.1038/leu.2013.225; Chng, W.J., Gertz, M.A., Chung, T.H., Van Wier, S., Keats, J.J., Baker, A., Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma (2010) Leukemia, 24, pp. 833-842; Boyd, K.D., Ross, F.M., Walker, B.A., Wardell, C.P., Tapper, W.J., Chiecchio, L., Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival (2011) Clin Cancer Res, 17, pp. 7776-7784; Moreau, P., Attal, M., Garban, F., Hulin, C., Facon, T., Marit, G., Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials (2007) Leukemia, 21, pp. 2020-2024; Kumar, S., Fonseca, R., Ketterling, R.P., Dispenzieri, A., Lacy, M.Q., Gertz, M.A., Trisomies in multiple myeloma: Impact on survival in patients with high-risk cytogenetics (2012) Blood, 119, pp. 2100-2105; Shi, L., Campbell, G., Jones, W.D., Campagne, F., Wen, Z., Walker, S.J., The microarray quality control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models (2010) Nat Biotechnol, 28, pp. 827-838; Meissner, T., Seckinger, A., Reme, T., Hielscher, T., Mohler, T., Neben, K., Gene expression profiling in multiple myeloma-reporting of entities, risk, and targets in clinical routine (2011) Clin Cancer Res, 17, pp. 7240-7247; Durie, B.G., Salmon, S.E., A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival (1975) Cancer, 36, pp. 842-854; Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., International staging system for multiple myeloma (2005) J Clin Oncol, 23, pp. 3412-3420; Waheed, S., Mitchell, A., Usmani, S., Epstein, J., Yaccoby, S., Nair, B., Standard and novel imaging methods for multiple myeloma: Correlates with prognostic laboratory variables including gene expression profiling data (2013) Haematologica, 98, pp. 71-78; Avet-Loiseau, H., Durie, B.G., Cavo, M., Attal, M., Gutierrez, N., Haessler, J., Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project (2013) Leukemia, 27, pp. 711-717; Neben, K., Jauch, A., Bertsch, U., Heiss, C., Hielscher, T., Seckinger, A., Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation (2010) Haematologica, 95, pp. 1150-1157; Lahuerta, J.J., Mateos, M.V., Martinez-Lopez, J., Rosinol, L., Sureda, A., De La Rubia, J., Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival (2008) J Clin Oncol, 26, pp. 5775-5782; Haessler, J., Shaughnessy Jr., J.D., Zhan, F., Crowley, J., Epstein, J., Van Rhee, F., Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling (2007) Clin Cancer Res, 13, pp. 7073-7079; Hoering, A., Crowley, J., Shaughnessy Jr., J.D., Hollmig, K., Alsayed, Y., Szymonifka, J., Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols (2009) Blood, 114, pp. 1299-1305; Barlogie, B., Anaissie, E., Haessler, J., Van Rhee, F., Pineda-Roman, M., Hollmig, K., Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma (2008) Cancer, 113, pp. 355-359; Harousseau, J.L., Avet-Loiseau, H., Attal, M., Charbonnel, C., Garban, F., Hulin, C., Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: Long-term analysis of the IFM 99-02 and 99-04 Trials (2009) J Clin Oncol, 27, pp. 5720-5726; Moreau, P., Attal, M., Pegourie, B., Planche, L., Hulin, C., Facon, T., Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial (2011) Blood, 117, pp. 3041-3044; Gay, F., Larocca, A., Wijermans, P., Cavallo, F., Rossi, D., Schaafsma, R., Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients (2011) Blood, 117, pp. 3025-3031; Paiva, B., Vidriales, M.B., Cervero, J., Mateo, G., Perez, J.J., Montalban, M.A., Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation (2008) Blood, 112, pp. 4017-4023; Paiva, B., Gutierrez, N.C., Rosinol, L., Vidriales, M.B., Montalban, M.A., Martinez-Lopez, J., High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma (2012) Blood, 119, pp. 687-691; Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma (2010) J Clin Oncol, 28, pp. 2077-2084; Kroger, N., Badbaran, A., Zabelina, T., Ayuk, F., Wolschke, C., Alchalby, H., Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma (2013) Biol Blood Marrow Transplant, 19, pp. 398-404; Hillengass, J., Ayyaz, S., Kilk, K., Weber, M.A., Hielscher, T., Shah, R., Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma (2012) Haematologica, 97, pp. 1757-1760; Zamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation (2011) Blood, 118, pp. 5989-5995; Kumar, S., Mahmood, S.T., Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Buadi, F.K., Impact of early relapse after auto-SCT for multiple myeloma (2008) Bone Marrow Transplant, 42, pp. 413-420; San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (2008) N Engl J Med, 359, pp. 906-917; Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study (2010) Lancet, 376, pp. 2075-2085; Sonneveld, P., Schmidt-Wolf, I.G., Van Der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 Trial (2013) J Clin Oncol, 30, pp. 2946-2955; Kumar, S.K., Mikhael, J.R., Buadi, F.K., Dingli, D., Dispenzieri, A., Fonseca, R., Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines (2009) Mayo Clin Proc, 84, pp. 1095-1110; Cavo, M., Sonneveld, P., Moreau, P., Blade, J., Goldschmidt, H., San Miguel, J., Impact of bortezomib incorporated into autotransplantation on outcomes of myeloma patients with high-risk cytogenetics: An integrated analysis of 1894 patients enrolled in four European Phase 3 Studies (2012) Blood, 120. , Abstract 749; Avet-Loiseau, H., Leleu, X., Roussel, M., Moreau, P., Guerin-Charbonnel, C., Caillot, D., Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p) (2010) J Clin Oncol, 28, pp. 4630-4634; Shaughnessy, J.D., Zhou, Y., Haessler, J., Van Rhee, F., Anaissie, E., Nair, B., TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3 (2009) Br J Haematol, 147, pp. 347-351; Neben, K., Lokhorst, H.M., Jauch, A., Bertsch, U., Hielscher, T., Van Der Holt, B., Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p (2012) Blood, 119, pp. 940-948; Morgan, G.J., Gregory, W.M., Davies, F.E., Bell, S.E., Szubert, A.J., Brown, J.M., The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis (2012) Blood, 119, pp. 7-15; Rajkumar, S.V., Gahrton, G., Bergsagel, P.L., Approach to the treatment of multiple myeloma: A clash of philosophies (2011) Blood, 118, pp. 3205-3211; Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Initial genome sequencing and analysis of multiple myeloma (2011) Nature, 471, pp. 467-472; Egan, J.B., Shi, C.X., Tembe, W., Christoforides, A., Kurdoglu, A., Sinari, S., Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides (2012) Blood, 120, pp. 1060-1066; Keats, J.J., Chesi, M., Egan, J.B., Garbitt, V.M., Palmer, S.E., Braggio, E., Clonal competition with alternating dominance in multiple myeloma (2012) Blood, 120, pp. 1067-1076; Shaughnessy Jr., J.D., Zhan, F., Burington, B.E., Huang, Y., Colla, S., Hanamura, I., A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 (2006) Blood, 109, pp. 2276-2284; Decaux, O., Lode, L., Magrangeas, F., Charbonnel, C., Gouraud, W., Jezequel, P., Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myelome (2008) J Clin Oncol, 26, pp. 4798-4805; Chng, W.J., Braggio, E., Mulligan, G., Bryant, B., Remstein, E., Valdez, R., The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition (2008) Blood, 111, pp. 1603-1609; Dickens, N.J., Walker, B.A., Leone, P.E., Johnson, D.C., Brito, J.L., Zeisig, A., Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome (2010) Clin Cancer Res, 16, pp. 1856-1864; Moreaux, J., Klein, B., Bataille, R., Descamps, G., Maiga, S., Hose, D., A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines (2011) Haematologica, 96, pp. 574-582; Hose, D., Reme, T., Hielscher, T., Moreaux, J., Messner, T., Seckinger, A., Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma (2011) Haematologica, 96, pp. 87-95; Kuiper, R., Broyl, A., De Knegt, Y., Van Vliet, M.H., Van Beers, E.H., Van Der Holt, B., A gene expression signature for high-risk multiple myeloma (2012) Leukemia, 26, pp. 2406-2413; Chung, T.H., Mulligan, G., Fonseca, R., Chng, W.J., A novel measure of chromosome instability can account for prognostic difference in multiple myeloma (2013) PLoS One, 8, pp. e66361


  • biomakers
  • prognosis
  • treatment
  • Consensus Development Conferences as Topic
  • Humans
  • Multiple Myeloma
  • Prognosis


Dive into the research topics of 'IMWG consensus on risk stratification in multiple myeloma'. Together they form a unique fingerprint.

Cite this